Alexandra J. Ambrico

Alexandra J. Ambrico

Auto-generated profile, based on publicly available information

Alexandra J. Ambrico

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2018 in Science
Verified
Journal Article
Closed access
PDF file
JAJean Albrengues
Jean Albrengues
MSMario A. Shields
Mario A. Shields
DNDavid Ng
David Ng
CPChun Gwon Park
Chun Gwon Park
AAAlexandra Ambrico
Alexandra Ambrico
MEMikala Egeblad
Mikala Egeblad
Waking up in a trap: Cancer patients who have undergone successful treatment can experience relapse of their disease years or even decades later. This is because cancer cells that have disseminated beyond the primary tumor site enter a state of dormancy, where they remain viable but not proliferating. Eventually, by mechanisms that are poorly understood, these clinically undetectable cells “wake up” and form actively growing metastases. Studying mouse models, Albrengues et al. found that sustained lung inflammation and the accompanying formation of neutrophil extracellular traps (NETs) could convert dormant cancer cells to aggressive lung metastases (see the Perspective by Aguirre-Ghiso). Awakening of these cells was associated with NET-mediated remodeling of the extracellular matrix and could be prevented by an antibody against the remodeled version of a matrix protein called laminin-111. Science , this issue p. eaao4227 ; see also p. 1314

15 May 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
DNDawid G. Nowak
Dawid G. Nowak
KKKsenya Cohen Katsenelson
Ksenya Cohen Katsenelson
KWKaitlin E. Watrud
Kaitlin E. Watrud
MCMuhan Chen
Muhan Chen
GMGrinu Mathew
Grinu Mathew
LTLloyd C Trotman
Lloyd C Trotman
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the common chromosome 16q deletion, which involves the AKT-suppressing phosphatase PHLPP2. Using RapidCaP, a genetically engineered mouse model of Pten/Trp53 mutant metastatic prostate cancer, we found that complete loss of Phlpp2 paradoxically blocks prostate tumor growth and disease progression. Surprisingly, we find that Phlpp2 is essential for supporting Myc, a key driver of lethal prostate cancer. Phlpp2 dephosphorylates threonine-58 of Myc, which renders it a limiting positive regulator of Myc stability. Furthermore, we show that small-molecule inhibitors of PHLPP2 can suppress MYC and kill PTEN mutant cells. Our findings reveal that the frequent hemizygous deletions on chromosome 16q present a druggable vulnerability for targeting MYC protein through PHLPP2 phosphatase inhibitors.

13 February 2017 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MCMuhan Chen
Muhan Chen
DNDawid G. Nowak
Dawid G. Nowak
NNNavneet Narula
Navneet Narula
BRBrian Robinson
Brian Robinson
KWKaitlin Watrud
Kaitlin Watrud
LTLloyd C Trotman
Lloyd C Trotman
Phosphatase and tensin homologue (PTEN) protein levels are critical for tumor suppression. However, the search for a recurrent cancer-associated gene alteration that causes PTEN degradation has remained futile. In this study, we show that Importin-11 (Ipo11) is a transport receptor for PTEN that is required to physically separate PTEN from elements of the PTEN degradation machinery. Mechanistically, we find that the E2 ubiquitin-conjugating enzyme and IPO11 cargo, UBE2E1, is a limiting factor for PTEN degradation. Using in vitro and in vivo gene-targeting methods, we show that Ipo11 loss results in degradation of Pten, lung adenocarcinoma, and neoplasia in mouse prostate with aberrantly high levels of Ube2e1 in the cytoplasm. These findings explain the correlation between loss of IPO11 and PTEN protein in human lung tumors. Furthermore, we find that IPO11 status predicts disease recurrence and progression to metastasis in patients choosing radical prostatectomy. Thus, our data introduce the IPO11 gene as a tumor-suppressor locus, which is of special importance in cancers that still retain at least one intact PTEN allele.

15 July 2016 in Cancer Research
Verified
Journal Article
Closed access
CSCarlos E. Stahlhut
Carlos E. Stahlhut
AAAlexandra J. Ambrico
Alexandra J. Ambrico
KWKaitlin E. Watrud
Kaitlin E. Watrud
HCHyejin Cho
Hyejin Cho
LWLily Wang
Lily Wang
LTLloyd Trotman
Lloyd Trotman
We describe our efforts to determine the effect of MYC and PI3K inhibition in a genetically engineered mouse model of naïve and castration-resistant metastatic prostate cancer. Metastasis is a major driver of mortality and morbidity in prostate cancer, the most common cancer type in men and the second leading cause of cancer-related deaths in the western world. To recapitulate the metastatic process in genetically engineered mice, we have developed the RapidCaP system, which uses prostate-directed viral infection to trigger focal loss of Pten and Trp53. Using luminescence and fluorescence, the RapidCaP system allows us to track disease progression in real-time and isolate metastases in distant tissues. This system provides a powerful platform for the identification and validation of candidate driver genes and for the efficient testing of novel therapeutics. Using this system, we have recently identified Myc as a critical, spontaneously activated driver in Pten-negative metastatic prostate cancer. Preliminary trials indicate that the Myc-suppressing Brd4 inhibitor JQ1 is ineffective towards primary disease, but induces metastatic regression. This specificity correlates with a switch from AKT-driven primary disease to MYC-driven metastatic disease. Our current efforts seek to determine how, when and why targeting of Myc using JQ1 and the PI 3-Kinase pathway using NVP-BKM120 can be best used to treat naïve and castration-resistant metastatic prostate cancer. In addition, we are examining changes to the transcriptome and epigenetic alterations that characterize Pten-negative metastatic prostate cancer, with the goal of understanding the mechanisms of progression toward a metastatic state and establishing new therapeutic targets. Citation Format: Carlos E. Stahlhut, Alexandra J. Ambrico, Kaitlin E. Watrud, Hyejin Cho, Lily Wang, Jun Qi, Lewis C. Cantley, James Bradner, Lloyd Trotman. Myc vs. Akt therapy in RapidCap, a GEM model for metastatic prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4165.